Publications by authors named "Senar Ebinc"

Claim this Profile
C
Correction: Kalkan et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. 2025, , 638.
Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz

Medicina (Kaunas)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of inflammatory indices in patients with metastatic non-small cell lung cancer.
Zuhat Urakçı, Zeynep Oruc, Halil Kömek, Senar Ebinç, Esra Pirinççi

Rev Assoc Med Bras (1992)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aşık

Sci Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study.
Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz

Medicina (Kaunas)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superiority of Pathologic Lymph Node Ratio over Positive Lymph Node Count in Operated Early-Stage Breast Cancer.
Zuhat Urakçı, Muhammet Ali Kaplan, Zeynep Oruç, Mahmut Gümüş, Doğan Uncu

Ann Ital Chir· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aşık

Sci Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience.
Yasin Sezgin, Ogur Karhan, Serdar Ileri, Senar Ebinc, Sezai Tunc

J Coll Physicians Surg Pak· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors.
Zuhat Urakçı, Senar Ebinç, Zeynep Oruc, Ziya Kalkan, Muhammet Ali Kaplan

Postgrad Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the role of 18 F-fluorodeoxyglucose PET/computed tomography and 68 Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma.
Yunus Güzel, Halil Kömek, Canan Can, İhsan Kaplan, Ferat Kepenek

Nucl Med Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Characteristics and Outcomes of Cancer Cases Among Syrian Refugees From Southern Turkey.
Tezer Kutluk, Berksoy Sahin, Meral Kirazli, Fahad Ahmed, Sinem Aydin

JAMA Netw Open· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer.
Zuhat Urakçı, Senar Ebinç, Sezai Tunç, Ziya Kalkan, Zeynep Oruç

Cureus· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür

BMC Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür

BMC Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
18 F-FDG PET/CT parameters for prediction of response to neoadjuvant therapy and prognosis in rectal cancer.
Senar Ebinç, Yunus Güzel, Zeynep Oruç, Halil Kömek, Ziya Kalkan

Nucl Med Commun· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer.
Senar Ebinç, Zeynep Oruç, Ziya Kalkan, Fatma Teke, Serdar Onat

Cureus· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma.
Senar Ebinç, Zeynep Oruç, Ziya Kalkan, Oğur Karhan, Zuhat Urakçı

Turk Gogus Kalp Damar Cerrahisi Derg· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of basal metabolic and volumetric F-FDG PET/CT parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.
Ferat Kepenek, Hüseyin Karaoğlan, Canan Can, Halil Kömek, İhsan Kaplan

Hell J Nucl Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thiol-disulphide Homeostasıs and Ischemia-modified Albumın Level and its Relatıonshıp with Clınicopathological Features of Breast Cancer.
Ugur Hunur, Zeynep Oruc, Senar Ebinc, Idris Oruc, Salim Neselioglu

J Coll Physicians Surg Pak· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer.
Senar Ebinç, Zeynep Oruç, Zuhat Urakçi, Ziya Kalkan, Muhammet Ali Kaplan

Eurasian J Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of [ Ga]Ga-DOTA-FAPI-04 PET/CT and [F]FDG PET/CT in colorectal cancer.
Halil Kömek, Canan Can, İhsan Kaplan, Cihan Gündoğan, Ferat Kepenek

Eur J Nucl Med Mol Imaging· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy.
Senar Ebinç, Zeynep Oruç, Yasin Sezgin, Oğur Karhan, Erkan Bilen

Future Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients.
Zeynep Oruç, Yunus Güzel, Senar Ebinç, Halil Kömek, Mehmet Küçüköner

Nucl Med Commun· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
Sema Sezgin Göksu, Ali Murat Tatlı, Çağlayan Geredeli, Mustafa Atcı, Ali Ayberk Besen

Cancer Chemother Pharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of gastrointestinal stromal tumors: A single-center experience.
Senar Ebinc, Zeynep Oruc

North Clin Istanb· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases.
Zeynep Oruç, M Ali Kaplan, Mustafa Karaağaç, Neslihan Özyurt, Ali Murat Tatlı

Future Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis